Mylan offers discounts on EpiPen amid criticism
It is latest firm to be caught up in outrage at apparently egregious drug price increases
Add BT as a preferred source
New York
MYLAN NV said on Thursday it would reduce the out-of-pocket costs of its emergency EpiPen allergy injection for some patients amid a wave of criticism from lawmakers and the public over the product's rapidly escalating price.
The list price of the drug will remain the same, but the company said it would increase the maximum copay assistance programme to US$300 from US$100 for patients who pay for the 2-pak in cash or who are covered by a commercial health insurer.
TRENDING NOW
Singtel Q1 gain drops 71% to S$818 million in absence of Airtel stake sale; weaker Singapore business
Sembcorp raises interim dividend despite 72% H1 profit slide to S$150 million on Alinta deal costs
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
CDL H1 profit jumps three times to S$301 million on strong condo sales, doubles interim dividend
